Elanco Animal Health (ELAN) Publishes FY18 Revenue Guidance

Elanco Animal Health (ELAN) Publishes FY18 Revenue Guidance

Elanco Animal Health (NASDAQ:ELAN) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.14-1.16 for the period, compared to the Thomson Reuters consensus estimate of $0.96. The company issued revenue guidance of $3.05-3.08 billion, compared to the consensus revenue estimate of $3.04 billion.

A number of equities research analysts recently weighed in on the company. BMO Capital Markets assumed coverage on Elanco Animal Health in a report on Wednesday, September 26th. They issued a market perform rating and a $33.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on Elanco Animal Health in a report on Monday, October 15th. They issued an overweight rating and a $38.00 price target on the stock. Cowen assumed coverage on Elanco Animal Health in a report on Monday, October 15th. They issued an outperform rating on the stock. Bank of America assumed coverage on Elanco Animal Health in a report on Monday, October 15th. They issued a neutral rating and a $34.00 price target on the stock. Finally, Goldman Sachs Group assumed coverage on Elanco Animal Health in a report on Monday, October 15th. They issued a neutral rating and a $30.00 price target on the stock. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and an average target price of $34.38.

ELAN stock traded up $1.25 on Tuesday, reaching $34.49. The company had a trading volume of 273,565 shares, compared to its average volume of 2,000,128. Elanco Animal Health has a 1 year low of $30.10 and a 1 year high of $37.61.

Elanco Animal Health (NASDAQ:ELAN) last posted its earnings results on Tuesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.04. The company had revenue of $761.10 million during the quarter, compared to analysts’ expectations of $766.26 million. During the same period in the previous year, the company posted $0.14 EPS. Elanco Animal Health’s quarterly revenue was up 9.2% compared to the same quarter last year.

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Monday, September 24th. The shares were purchased at an average price of $24.00 per share, with a total value of $240,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jeffrey N. Simmons bought 22,000 shares of Elanco Animal Health stock in a transaction that occurred on Monday, September 24th. The stock was bought at an average cost of $24.00 per share, for a total transaction of $528,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 33,000 shares of company stock worth $792,000.

Elanco Animal Health Company Profile

There is no company description available for Elanco Animal Health Inc

Read More: Tariff

Related posts

Leave a Comment